Queen's Medical Research Institute
Edinburgh, Midlothian, EH16 4TJ, United Kingdom
NCT Number: NCT03626584
PET scanning (positron emission tomography) is a well-established technique used to identify areas of interest within the body. It involves injecting a radioactive tracer which highlights abnormal areas. It has recently been combined with CT (computed tomography) and MRI (magnetic resonance imaging) scanning to more accurately identify abnormalities within the heart. Cardiac amyloidosis, a condition which causes thickening of heart muscle due to abnormal protein deposits, is of particular interest. There are different forms of this condition and at present samples of tissue need to be taken and analysed in order to assess these accurately, which carries risks.
The study makes use of hybrid PET/MR scanning using a designated scanner which enables PET scanning combined with MRI scanning. The investigators will use a PET tracer which is widely used in cardiac imaging as it is hoped this will enable characterisation of abnormal areas within the heart in this condition in a way which hasn't been done before.
All participants will undergo PET scanning, where a radioactive tracer is injected into a vein before the scan. The radioactive substance only lasts for a short time and is safe, passed out of the body in urine. If successful, this imaging method will enable us to detect differences between different forms of cardiac amyloidosis in a non-invasive way, improving the diagnostic capabilities in this condition.
Looking for future studies?
Notify Me50 year and older
All sexes
Observational
Edinburgh, Midlothian, EH16 4TJ, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Hybrid 18F-NaF PET/MR imaging for observational diagnostic purposes
Time frame: 1 year
Quantification of myocardial PET tracer uptake
University of Edinburgh
Other
Molecular Imaging in Cardiovascular Disease Using Hybrid Positron Emission Tomography/Magnetic Resonance Imaging (PET/MR): Cardiac Amyloidosis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05184088
AL Amyloidosis, ATTR Amyloidosis
Kansas City, Kansas, United States
View Trial DetailsNCT06201832
Amyloid Neuropathies, Amyloid Neuropathies, Familial
La Marsa, Tunis Governorate, Tunisia
View Trial DetailsNCT06788535
Amyloid Neuropathies, Amyloid Neuropathies, Familial
Scottsdale, Arizona, United States
View Trial DetailsNCT04862273
Amyloid Neuropathies, Amyloid Neuropathies, Familial
Leipzig, Saxony, Germany
View Trial Details